We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed the most recent trading day at $97.79, moving +2.42% from the previous trading session. This change outpaced the S&P 500's 0.62% gain on the day. On the other hand, the Dow registered a gain of 0.99%, and the technology-centric Nasdaq increased by 0.65%.
Prior to today's trading, shares of the medical device manufacturer had gained 1.75% outpaced the Medical sector's loss of 1.22% and the S&P 500's gain of 0.59%.
The investment community will be paying close attention to the earnings performance of Boston Scientific in its upcoming release. The company is slated to reveal its earnings on February 4, 2026. The company's upcoming EPS is projected at $0.78, signifying a 11.43% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $5.27 billion, indicating a 15.44% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.04 per share and a revenue of $20.06 billion, indicating changes of +21.12% and 0%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Boston Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.08% higher. Boston Scientific is currently a Zacks Rank #2 (Buy).
In terms of valuation, Boston Scientific is presently being traded at a Forward P/E ratio of 27.65. This expresses a premium compared to the average Forward P/E of 19.35 of its industry.
One should further note that BSX currently holds a PEG ratio of 1.69. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.71.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 162, placing it within the bottom 34% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Beats Stock Market Upswing: What Investors Need to Know
Boston Scientific (BSX - Free Report) closed the most recent trading day at $97.79, moving +2.42% from the previous trading session. This change outpaced the S&P 500's 0.62% gain on the day. On the other hand, the Dow registered a gain of 0.99%, and the technology-centric Nasdaq increased by 0.65%.
Prior to today's trading, shares of the medical device manufacturer had gained 1.75% outpaced the Medical sector's loss of 1.22% and the S&P 500's gain of 0.59%.
The investment community will be paying close attention to the earnings performance of Boston Scientific in its upcoming release. The company is slated to reveal its earnings on February 4, 2026. The company's upcoming EPS is projected at $0.78, signifying a 11.43% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $5.27 billion, indicating a 15.44% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.04 per share and a revenue of $20.06 billion, indicating changes of +21.12% and 0%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Boston Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.08% higher. Boston Scientific is currently a Zacks Rank #2 (Buy).
In terms of valuation, Boston Scientific is presently being traded at a Forward P/E ratio of 27.65. This expresses a premium compared to the average Forward P/E of 19.35 of its industry.
One should further note that BSX currently holds a PEG ratio of 1.69. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.71.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 162, placing it within the bottom 34% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.